FluoGuide A/S Publishes Interim Report for the Period January - March 2024

30 May 2024
·
Deals
www.biospace.com
Financial StatementClinical ResultPhase 2
KØBENHAVN, DK / ACCESSWIRE / May 30, 2024 / FluoGuide A/S (STO:FLUO) Copenhagen, Denmark, 30 May 2024 - FluoGuide A/S ("FluoGuide" or the "Company") today releases its results for the period 1 January - 31 March 2024. The Q1 report is available as an attached document to this press release and on FluoGuide's website. FluoGuide had no revenue for the period and posted a net loss of DKK 7,521 thousand (DKK 9,535 thousand) for the period 1 January to 31 March 2024. The financial result for the period is in line with the Company's development plans. The total number of shares as of March 31, 2024, amounted to 12,208,384 shares. The total number of shares as of March 31, 2023, amounted to 11,814,500 shares. The average number of shares in Q1 2024 amounted to 12,208,384 shares. KEY FIGURES Q1 24 Q1 23 YTD 2024 YTD 2023 2023 DKK thousand 1-Jan-24 1-Jan-23 1-Jan-24 1-Jan-23 1-Jan-23 31-Mar-24 31-Mar-23 31-Mar-24 31-Mar-23 31-Dec-23 Net Revenue - - - - - Income before interest and tax (EBIT) -8,345 -11,645 -8,345 -11,645 -43,924 Net result for the period -7,521 -9,535 -7,521 -9,535 -38,377 Cash and bank 10,683 16,269 10,683 16,269 21,668 Solvency ratio (%) 29% 82% 29% 82% 43% Result per share (DKK) -0.62 -0.81 -0.62 -0.81 -3.22 HIGHLIGHTS DURING Q1: FluoGuide provides strategic update and outlines development plans towards commercialization of FG001 FluoGuide enters collaboration within robot assisted head & neck cancer surgery with Intuitive Surgical, a world leading robotic-assisted surgery company Two new board members, Donna Haire (regulatory profile) and Roger Gunnarsson (financial profile) HIGHLIGHTS AFTER Q1 FluoGuide selects laser system for photothermal cancer therapy with FG001 "FluoGuide published a collaboration with Intuitive Surgical in head & neck surgery which on top of the three positive clinical study phase II results published last year supports our long-term objective of improving the outcome for patients with cancer." says Morten Albrechtsen, CEO at FluoGuide. Certified Adviser: Svensk Kapitalmarknadsgranskning AB About FluoGuide FluoGuide is a biotech company specializing in precision cancer surgery. FluoGuide's lead product, FG001, is designed to enhance surgical accuracy by illuminating cancer cells intraoperatively using fluorescent light, which binds to the uPAR receptor, widely expressed in most solid cancer types. It is anticipated that FG001 will decrease both the incidence of local recurrence after surgery and surgical complications, improving cancer treatment and outcomes for patients, while also reducing healthcare costs. Moreover, FluoGuide's technology platform may also be utilized for photothermal therapy (PTT), which kills cancer cells through heating them with the use of near-infrared light. A technique that spares healthy surrounding tissue from damage, offering a direct therapeutic effect of FG001, further benefiting patients undergoing cancer surgery. FluoGuide is listed on the Nasdaq First North Growth Market in Stockholm under the ticker symbol "FLUO." For more information about FluoGuide's pipeline, technology, and upcoming events, visit Attachments FluoGuide Q1 2024 SOURCE: FluoGuide A/S View the original press release on accesswire.com
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.